These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16820704)

  • 41. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
    J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs.
    Jonas M; Ambroziak U; Bednarczuk T; Nauman J
    Endokrynol Pol; 2006; 57(6):596-604. PubMed ID: 17253432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
    Mazza E; Carlini M; Flecchia D; Blatto A; Zuccarini O; Gamba S; Beninati S; Messina M
    J Endocrinol Invest; 2008 Oct; 31(10):866-72. PubMed ID: 19092290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC; Coeli CM; Vaisman M
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
    Choi YM; Kwak MK; Hong SM; Hong EG
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
    Hwang S; Shin DY; Song MK; Lee EJ
    Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Disease.
    Ozçelik S; Celik M; Vural A; Aydin B; Gozu H
    J Coll Physicians Surg Pak; 2021 May; 31(5):517-522. PubMed ID: 34027861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TSH-receptor antibodies determined by the first, second and third generation assays and thyroid-stimulating antibody in pregnant patients with Graves' disease.
    Kamijo K
    Endocr J; 2007 Aug; 54(4):619-24. PubMed ID: 17641440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders.
    Cardia MS; Lima N; Knobel M; Medeiros-Neto G
    Thyroid; 2004 Apr; 14(4):295-300. PubMed ID: 15142363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.